◀ Anchor ▶
You may remember the’Invossa Incident’ when it was in the limelight as the world’s first arthritis cell treatment, and the fact of manipulating ingredients was revealed.
Two court rulings over Invossa came out today.
The decision that it was right to revoke the manufacturing and marketing license as a serious defect in’manipulation of ingredients’ was recognized.However, on the same day, in another court, the executives of the development company who were accused of participating in the manipulation were found acquitted.
Reporter Yoon Soo-han will explain why the results are so mixed.
◀ Report ▶
‘Invossa Keiju’, the first gene therapy product in Korea and the world’s first arthritis cell therapy in 2017.
After more than 3,000 people had already used this drug, the fact of the manipulation of ingredients by the developer, Kolon Life Sciences, was revealed.
When the Ministry of Food and Drug Safety canceled the manufacturing and marketing license of Invossa, Kolon protested and filed a lawsuit, but it was useless.
The Seoul Administrative Court gave the hand of the Ministry of Food and Drug Safety, saying, “A serious defect was found in the process of licensing medicines directly related to life and health.”
However, Kolon executives who were accused of falsifying the results of the experiment to obtain permission were indulged.
The court pleaded not guilty to Kolon executives, saying, “Kolon’s side concealed the results of an unfavorable experiment and provided false data.”
Because the Food and Drug Administration, who was deceived by the false data, could not verify it, there is no criminal responsibility for the deceived developer.
[엄태섭/’인보사’ 피해자 변호인]
“(Although I was innocent), all of the illegal acts of Kolon Life Sciences, and in simple terms, hierarchies (deception), were all acknowledged.”
The prosecution said it would appeal immediately.
As such, it is noteworthy whether Kolon’s responsibility has not been recognized since the first trial of the’Invossa excommunication’, and whether it will affect the trial of former chairman Lee Woong-yeol in the midst of a court battle.
Former chairman Lee, who took special care of’Invossa’s my son’, is being tried on suspicion of raising stock prices by concealing the fact that the clinical trial was suspended and involved in the manipulation of ingredients.
This is Suhan Yoon at MBC News.
(Video coverage: Hyun Ki-taek / Video editing: Actor Jin)
MBC News awaits your report 24 hours a day.
▷ Phone 02-784-4000
▷ Email [email protected]
▷ KakaoTalk @mbc report
– .
